Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial

14 May 2015

Abstract excerpt

OBJECTIVES: Outer membrane vesicle (OMV) vaccines are used against outbreaks of capsular group B Neisseria meningitidis (MenB) caused by strains expressing particular PorA outer membrane proteins (OMPs). Ferric enterobactin receptor (FetA) is another variable OMP that induces type-specific bactericidal antibodies, and the combination of judiciously chosen PorA and FetA variants in vaccine formulations is a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacterial Infections and Vaccines
Share to Neonatal and Maternal Infections
Share to Pneumonia and Respiratory Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25982025
DOI: 10.1016/j.jinf.2015.05.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trialPMID 25982025Read ↗

FetA Antibodies Induced by an Outer Membrane Vesicle Vaccine Derived from a Serogroup B Meningococcal Isolate with Constitutive FetA Expression.Semantic proximity Read ↗

BexseroSemantic proximity Read ↗

OpcA and PorB are novel bactericidal antigens of the 4CMenB vaccine in mice and humansSemantic proximity Read ↗

The Development of a Vaccine Against Meningococcus B Using Reverse VaccinologySemantic proximity Read ↗

Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigenSemantic proximity Read ↗

Meningococcal serogroup B vaccines: Estimating breadth of coverageSemantic proximity Read ↗

MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccineSemantic proximity Read ↗

Impact of MenBvac, an outer membrane vesicle (OMV) vaccine, on the meningococcal carriageSemantic proximity Read ↗

From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccineSemantic proximity Read ↗

Bexsero® chronicleSemantic proximity Read ↗

Bioinformatic analysis of meningococcal Msf and Opc to inform vaccine antigen design.Semantic proximity Read ↗

Novel approaches to Neisseria meningitidis vaccine designSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.